Abstract
Anthracyclines are routinely used in cancer chemotherapy in many childhood cancers. A serious adverse effect of doxorubicin chemotherapy is cardiotoxicity which may lead to congestive heart failure for long-term survivors years after treatment. Currently, echocardiography is used to control the heart function during anthracyclines therapy. B-type natriuretic peptide (BNP) and NT-proBNP as well as cardiac troponins have been proposed as clinical markers for subclinical anthracycline-induced cardiotoxicity. The BNP and pro-BNP can be easily measured in plasma and initial data indicate that the NT-proBNP could be sensitive predictor for the development of congestive heart failure.
Lingua originale | English |
---|---|
pagine (da-a) | 1311-1321 |
Numero di pagine | 11 |
Rivista | BIOMEDICAL & PHARMACOLOGY JOURNAL |
Volume | 15 |
DOI | |
Stato di pubblicazione | Pubblicato - 2022 |
Keywords
- Anthracyclines
- Troponin
- pro-BNP
- Children